GlassScriptPhysician profile
Andrew Harris
NPI 1154713626
$1,784.46
in general payments reported to CMS, 2019-2025
25 companies · $778 in 2025
The $778 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $155 · 2021: $135 · 2023: $83.00 · 2024: $299 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $195.23 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $187.39 | 2019-2025 | Repatha |
| Boston Scientific Corporation | $183.04 | 2025 | Watchman Flx, Ams 800 Artificial Urinary Sphincter |
| Novartis Pharmaceuticals Corporation | $144.12 | 2025 | |
| Pfizer INC. | $141.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $119.53 | 2024 | Voquezna |
| Exact Sciences Corporation | $114.81 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $75.04 | 2019-2021 | |
| Lilly USA, LLC | $61.75 | 2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $50.43 | 2019-2020 | |
| Novo Nordisk INC | $47.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $46.74 | 2025 | Wainua |
| Abbvie INC. | $33.95 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.84 | 2020-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.56 | 2020 | |
| Globus Medical, INC. | $31.07 | 2025 | Senza |
| Dexcom, INC. | $26.78 | 2025 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $26.73 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $22.77 | 2025 | Optimizer |
| Madrigal Pharmaceuticals | $22.09 | 2025 | Rezdiffra |
| Blueprint Medicines Corporation | $19.45 | 2024 | Ayvakit |
| Chiesi USA, INC. | $16.18 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.67 | 2019 | |
| Medicomp INC | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.